World-leading imaging technology reveals insights into cancer treatment for children with Down Syndrome

World-leading imaging technology reveals insights into cancer treatment for children with Down Syndrome.

The National Imaging Facility (NIF) continues to enable imaging science to unlock major health challenges with break-through research coming out of the South Australian Health and Medical Research Institute (SAHMRI).

Leading-edge research conducted at the NIF’s South Australian Node has provided critical insight into the development of cancer in children with Down Syndrome.

Scientists from SAHMRI have identified an epigenetic regulator, HMGN1, on chromosome 21 that cooperates with a high-risk gene fusion to give rise to acute lymphoblastic leukaemia (ALL) in paediatric patients with Down Syndrome.

Children with Down Syndrome are 20 times more prone to developing leukaemia, and are more susceptible to experiencing additional side effects from chemotherapy. In addition to these statistics, 60% of children with Down Syndrome ALL harbour this high-risk gene fusion, and all have high expression of chromosome 21 genes.

SAHMRI’s findings suggest HMGN1 is a potential target for a precision treatment approach in Down Syndrome ALL. The outcomes from this study present an opportunity to reduce exposure in patients to the toxic side effects of chemotherapy and improve survival outcomes for children with Down Syndrome ALL.

NIF Node Co-Director, Dr Chris Christou praised the work of the SAHMRI team, including Prof Deborah L White and Dr Elyse Page and congratulated them on the findings which present potentially life-saving data.

“These dedicated and highly-skilled scientists have demonstrated the critical role imaging has in responding to major health challenges,” Dr Christou said.

“I congratulate them on this vital discovery and look forward to updates on their continued work progressing their research to improve the lives of children with Down Syndrome.”

You can read a detailed post about the study here.

For more information, contact Wick Lakshantha, Imaging Scientist and National Imaging Facility Fellow, SAHMRI.

Development of Microbeam Radiation Therapy

Only two in ten people diagnosed with brain cancer will survive for at least five years, a figure that has barely improved in the last 30 years. Due to the blood-brain barrier and the risk of damaging normal brain tissue, brain cancer treatments are complex and multidisciplinary. Despite advances in surgical techniques, radiotherapy and chemotherapeutics, brain tumours remain challenging to treat. Hence, image-guided microbeam radiation therapy (MRT) with nanoparticle enhancement is being investigated for the treatment of brain cancer in animal models.

Read More

Cancer cells killed by honeybee venom

Breast cancer, the most common cancer in women worldwide, may one day be treated using the venom of the European honeybee.

Dr Ciara Duffy from Western Australia’s Harry Perkins Institute of Medical Research has found that venom from honeybees can rapidly kill aggressive and hard-to-treat breast cancer cells. NCRIS-enabled facilities at the Centre for Microscopy, Characterization and Analysis (CMCA), UWA, were integral to the research, published recently in the journal Nature Precision Oncology.

Read More
Privacy Settings
Youtube
Vimeo
Google Maps